IDH2 and glioma: While less than 5% of CpG sites are hypermethylated in other IDH-mutant cancers, approximately 20% of CpG sites are hypermethylated in IDH-mutant gliomas compared to their wild-type IDH counterparts, suggesting that gliomas with IDH mutations have unique molecular features [31].